Diagnostic Products (NYSE:DP)
Historical Stock Chart
From May 2019 to May 2024
Diagnostic Products Corporation (NYSE:DP) today
announced that they have recently begun shipping the Immunoassay
Workcell, a high volume automated immunoassay testing system. An
extensive testing program and a controlled launch plan have proven the
reliability of the system and demonstrated its ability to
significantly improve laboratory productivity.
DPC's Sample Management System (SMS) is used to create the
Immunoassay Workcell, which combines two IMMULITE 2000 systems, two
IMMULITE 2500 systems, or a combination of the two systems. The
Immunoassay Workcell is designed to meet the needs of the high volume
testing facilities to provide flexibility with productivity for
immunoassay testing. The system operator now has access to 48
different assays and 9,600-reagent tests from a single sample entry
point, allowing up to 5 hours of usable walk-away time. A unique
advantage of the Immunoassay Workcell is that it processes patient
samples on a tube-by-tube basis, as opposed to the more conventional
rack loading technique. The Immunoassay Workcell also simplifies
operation by allowing the laboratory technician to interface with the
entire system via a single workstation.
"This is great news for both DPC and our customers," said Sidney
A. Aroesty, President, COO, DPC. "With approximately 4,000 IMMULITE
2000 and IMMULITE 2500 systems placed worldwide, it is clear that
these systems are meeting the needs of many laboratories in a variety
of testing environments. The addition of our Immunoassay Workcell will
offer even more flexibility in processing immunoassay tests and will
increase productivity and provide operators more usable walk-away time
to perform other duties in the lab. The fact that the SMS can be
linked to a track-based laboratory automation system further expands
our flexibility to meet the needs of our customers. This is the
'powerhouse' in the family of IMMULITE systems."
About Diagnostic Products Corporation
Diagnostic Products Corporation, founded in 1971, is the global
leader dedicated exclusively to immunodiagnostics. DPC's product menu
includes over 75 immunoassays and more than 365 specific allergens and
allergy panels. In addition, DPC addresses the chemistry and
laboratory automation testing needs of its customers through
partnerships with manufacturers of chemistry systems and reagents. The
combined chemistry and immunoassay menu is one of the largest and most
diversified available, covering most laboratory tests requested. DPC
also designs and manufactures automated laboratory instrumentation,
which provides fast, accurate results while reducing labor and reagent
costs. DPC sells its products to hospitals, clinics and laboratories
in more than 100 countries.
Additional Company information can be found on DPC's website at
www.dpcweb.com.
Except for the historical information contained herein, this press
release contains forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially.
These factors include the effects of governmental or other actions
relating to the FDA's decision that its Application Integrity Policy
should be applied to the Company or relating to the Company's Chinese
affiliate; the rate of customer demand for the Company's products; the
Company's ability to successfully market new and existing products;
its dependence on certain suppliers; domestic and foreign government
regulation; its ability to keep abreast of technological innovations
and to translate them into new products; competition; political and
economic instability in certain markets including the movements of
foreign currencies relative to the dollar; and other risks and
uncertainties disclosed from time to time in the Company's SEC reports
and filings.